10 Best Immunotherapy Stocks To Buy Now

Published on October 11, 2022 at 11:54 am by Usman Kabir in Hedge Funds, News

In this article, we discuss 10 best immunotherapy stocks to buy now. If you want to read about some more immunotherapy stocks, go directly to 5 Best Immunotherapy Stocks To Buy Now.

The global immunotherapy market is rapidly evolving as technological, regulatory, and economic trends combine to alter the growth and risk dynamics within the industry. According to a report by market research firm BCC Research, the global market for immunotherapy drugs could be worth more than $204 billion in value by 2025, up from $139 billion in 2020, representing an annual growth rate of close to 8%. The estimates are based on analysis of new products, regulatory scenarios, and the challenges and opportunities affecting market growth.

Within the immunotherapy universe, cancer immunotherapies are the largest market. According to data compiled by the American Cancer Society, of all drug approvals between 2010 and 2018, 27% were cancer therapies, compared with 4% in the 1980s. Despite this explosive growth, cancer remains the leading cause of death globally, accounting for nearly 10 million deaths in 2020. To put this figure into context, the coronavirus pandemic killed about 3 million people in the same year.

Growth Drivers and Challenges Abound for Immunotherapy Marketplace

Investors eager to take advantage of the growth opportunities in the sector should monitor some of the best immunotherapy stocks that include Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV). In recent years, immunotherapy research has evolved to include trials studying combinations such as kill switches, removable protein masks, or linkers that bring immune cells and tumor cells into proximity in order to tamp down side-effects.

There are several reasons that are holding back even faster development within the immunotherapy marketplace. These include the high cost of cancer immunotherapies, strict rules and regulations related to government policies in some regions, manufacturing process related complexities, and concern regarding side effects. The growth drivers, on the other hand, include the increasing prevalence of autoimmune diseases among adults and growing investments in the research and funding of cancer.

Our Methodology

The companies that operate in the immunotherapy sector were selected for the list. In order to provide readers with some additional context for their investment choices, the business fundamentals and analyst ratings for these stocks are also discussed. The latest pipeline drugs of these firms, under various stages of their development, are mentioned as well for further clarity. A database of around 900 elite hedge funds tracked by Insider Monkey in the second quarter of 2022 was used to identify the number of hedge funds that hold stakes in each firm.

Best Immunotherapy Stocks To Buy Now

10. Evaxion Biotech A/S (NASDAQ:EVAX)

Number of Hedge Fund Holders: 2

Evaxion Biotech A/S (NASDAQ:EVAX) is a clinical-stage biotech company that engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. It is one of the best immunotherapy stocks to invest in. Evaxion Biotech A/S (NASDAQ:EVAX) recently revealed that it enrolled the first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the US, Europe, and Australia in collaboration with drug giant Merck, which is supplying the trial with its blockbuster drug Keytruda.

On July 18, investment advisory Oppenheimer assumed coverage of Evaxion Biotech A/S (NASDAQ:EVAX) stock with an Outperform rating and a $16 price target. Analyst Jeff Jones issued the ratings update.

At the end of the second quarter of 2022, 2 hedge funds in the database of Insider Monkey held stakes worth $185,000 in Evaxion Biotech A/S (NASDAQ:EVAX), compared to 2 in the previous quarter worth $1.3 million.

Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Citadel Investment Group is a leading shareholder in Evaxion Biotech A/S (NASDAQ:EVAX), with 333,100 shares worth more than $650,000.

Just like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Evaxion Biotech A/S (NASDAQ:EVAX) is one of the best immunotherapy stocks to buy right now.

9. ThermoGenesis Holdings, Inc. (NASDAQ:THMO)

Number of Hedge Fund Holders: 3

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It is one of the top immunotherapy stocks to invest in. The company currently markets a full suite of solutions for automated clinical bio-banking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.

On August 11, the company reported earnings for the second quarter of 2022, posting a revenue of $3 million, up more than 37% compared to the revenue over the same period last year. The firm is based in California and was founded in 1986.

At the end of the second quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $68,000 in ThermoGenesis Holdings, Inc. (NASDAQ:THMO). Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Citadel Investment Group is a leading shareholder in ThermoGenesis Holdings, Inc. (NASDAQ:THMO), with 195,192 shares worth more than $54,000.

8. Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Number of Hedge Fund Holders: 6

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is a clinical stage biopharmaceutical company that focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. It is one of the premier immunotherapy stocks to invest in. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) recently entered into an Open Market Sale Agreement with Jefferies, wherein it may issue and sell from time to time shares at a par value of $0.001 per unit. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) also recently reported that the US Food and Drug Administration had removed a clinical hold on a phase 3 trial of a breast cancer treatment, allowing the trial to progress.

On July 12, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock with a $78 price target, predicting that the FLAMINGO-01 breast cancer trial of the firm would proceed as planned.

Among the hedge funds being tracked by Insider Monkey, NewYork-based investment firm Renaissance Technologies is a leading shareholder in Greenwich LifeSciences, Inc. (NASDAQ:GLSI), with 105,159 shares worth more than $891,000. At the end of the second quarter of 2022, 6 hedge funds in the database of Insider Monkey held stakes worth $2.8 million in Greenwich LifeSciences, Inc. (NASDAQ:GLSI), compared to 1 the preceding quarter worth $410,000.

7. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 8

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company that engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It is one of the major immunotherapy stocks to invest in. ImmunityBio, Inc. (NASDAQ:BRX) recently revealed that the drug authorities in the US had accepted for review the company’s biologics license application (BLA) for its agonist N-803, a treatment of bladder cancer carcinoma in situ. The exact indication for N-803 is for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.

On August 03, Jefferies analyst Kelly Shi initiated coverage of ImmunityBio, Inc. (NASDAQ:BRX) stock with a Buy rating and lowered price target to $8 from $10, stressing that the price target is lowered to reflect the recent pullback and current market conditions.

At the end of the second quarter of 2022, 8 hedge funds in the database of Insider Monkey held stakes worth $11 million in ImmunityBio, Inc. (NASDAQ:IBRX), compared to 7 the preceding quarter worth $7 million.

6. UroGen Pharma Ltd. (NASDAQ:URGN)

Number of Hedge Fund Holders: 11

UroGen Pharma Ltd. (NASDAQ:URGN) is a biotechnology company that engages in the development and commercialization of novel solutions for specialty cancers and urothelial diseases. It is one of the elite immunotherapy stocks to invest in. UroGen Pharma Ltd. (NASDAQ:URGN) stock has risen in the past week after the company said that the US FDA had authorized an extension of the in-use period for Jelmyto (mitomycin) for pyelocalyceal solution admixture from 8 hours to 96 hours after reconstitution of the product.

On April 27, Berenberg analyst Anita Dushyanth initiated coverage of UroGen Pharma Ltd. (NASDAQ:URGN) stock with a Buy rating and a $20 price target, denoting that there was a considerable opportunity for UroGen’s novel RTGel drug-delivery technology in both high- and low-grade bladder cancers given that bladder cancer has a high rate of recurrence and is currently being treated predominantly with surgery.

Among the hedge funds being tracked by Insider Monkey, Oregon-based investment firm Stonepine Capital is a leading shareholder in UroGen Pharma Ltd. (NASDAQ:URGN), with 1.1 million shares worth more than $9 million. At the end of the second quarter of 2022, 11 hedge funds in the database of Insider Monkey held stakes worth $33 million in UroGen Pharma Ltd. (NASDAQ:URGN), compared to 9 the preceding quarter worth $19 million.

In addition to Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best immunotherapy stocks to buy right now according to smart investors.

Click to continue reading and see 5 Best Immunotherapy Stocks To Buy Now.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on October 30, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up